Edit

HanchorBio Inc.

https://www.hanchorbio.com/

Last activity: 09.09.2026

Active

Categories: BioTechClinicalImmunologyOncologyTherapeutics

The culture of emphasis on innovation, quality, and speed will remain and be nourished, To transcend the Immuno-Oncology therapeutics by developing cutting-edge designer biologics with innovative modalities for cancer patients.

Mentions

Location: Taiwan

Investors 2

Date	Name	Website
12.01.2023	Korea Inve...	partners.k...
-	Panacea Ve...	panaceaven...

Mentions in press and media 19

Date	Title	Description
09.09.2026	HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit	HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827)...
09.07.2026	HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership	Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- HanchorBio...
26.05.2026	HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29	TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced...
24.04.2026	HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma	Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology com...
25.03.2026	HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering	Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 20...
13.02.2026	HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer	First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generat...
05.02.2026	HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026	Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorB...
26.01.2026	HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline	SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologic...
26.01.2026	WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline	SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanc...
11.12.2025	HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025	International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- Hancho...
08.12.2025	HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025	Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ --...
07.11.2025	HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers	Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. ...
05.11.2025	HanchorBio Presents Preclinical Data on HCB301 at SITC 2025	HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SH...
24.10.2025	HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity	FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 782...
23.10.2025	HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology	Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and S...
21.10.2025	HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101	TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the Unite...
20.10.2025	HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025	Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/...
01.07.2025	HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach	TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the si...
17.06.2025	HanchorBio Presents Promising Data on HCB101 Checkpoint Inhibitor Immunotherapy at ASCO	Interim data on the cancer treatment shows robust potential for balancing efficacy and safety TAIPEI and SHANGHAI and SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- Following a successful launch of Phase 2 clinical trials in March, HanchorBio...

HanchorBio Inc.

Investors 2

Mentions in press and media 19

Reviews 0